Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
DOR agonist
Dual agonist
KOR agonist
Opioid
Oxabicyclo[3.2.1]octane structure
Journal
Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
30
10
2021
revised:
27
11
2021
accepted:
29
11
2021
pubmed:
12
12
2021
medline:
24
2
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
The κ opioid receptor (KOR) is one of the promising targets to develop analgesics lacking morphine like side effects. To seek a novel KOR agonist we designed 6-amide derivatives with an oxabicyclo[3.2.1]octane structure based on a proposed active conformation of a selective KOR agonist nalfurafine. All the synthesized compounds strongly bound to the KOR and some compound showed KOR selectivities. 6R-Amides were more potent and efficacious KOR agonists than the corresponding 6S-isomers. However, most 6-amide derivatives were partial KOR agonist. Conformational analyses of 6R- and 6S-amide derivatives and nalfurafine well accounted for the difference of KOR agonistic activities between two diastereomers. Surprisingly, the tested N-H amides were full δ opioid receptor (DOR) agonists. Among the tested compounds 7a with benzamide moiety was the most potent dual DOR/KOR agonist. On the other hand, 6S-phenylacetamide 8b was potent full DOR agonist with less efficacious agonist activity for the μ receptor and KOR. 6-Amide derivatives with an oxabicyclo[3.2.1]octane structure were expected to be a promising fundamental skeleton for the dual DOR/KOR agonists and/or selective DOR agonists.
Identifiants
pubmed: 34894610
pii: S0968-0896(21)00560-5
doi: 10.1016/j.bmc.2021.116552
pii:
doi:
Substances chimiques
Analgesics
0
Morphinans
0
Receptors, Opioid, delta
0
Receptors, Opioid, kappa
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116552Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.